Moreover, such mechanistic insights highlight the necessity of considering both the specific RAS mutation and the broader cellular context when developing and applying RAS-targeted therapies, which helps to explain why certain inhibitors may demonstrate greater efficacy in specific cancer types or against particular KRAS mutations. This evidence concerns the gene KRAS and cancer.